Dovramilast

Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (HY-B0329) -mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) [1].

Product Specifications

CAS Number

[340019-69-4]

Product Name Alternative

CC-11050

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dovramilast.html

Purity

99.66

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1CC1)NC2=CC=CC(CN3[C@@H](C4=CC=C(OC)C(OCC)=C4)CS(=O)(C)=O)=C2C3=O

Molecular Formula

C24H28N2O6S

Molecular Weight

472.55

Precautions

H302, H315, H319

References & Citations

[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 36, No. 2, 2022.|[2]Selvakumar Subbian, et al. Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis. Front Immunol. 2016 Jun 17;7:238.